The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1, 2, 3, or 4; Z represents O, S, NR.sup.6, SO or SO.sub.2; R.sup.1 represent hydrogen, cyano, hydroxy, or C.sub.1-4alkyl optionally substituted with halo, R.sup.2 represents hydrogen, C.sub.1-4alkyl, or C.sub.1-4alkyloxy-; R.sup.3 represents hydrogen, C.sub.1-4alkyl, C.sub.1-4alkyloxy- or R.sup.3 combined with R.sup.2 form together a divalent radical selected from the group consisting of --O--CH.sub.2-- (a), --NR.sup.7--CH.sub.2-- (b), --(CR.sup.8R.sup.9).sub.m-- (c) and --CR.sup.10.dbd. (d) wherein m represents 1 or 2 and R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are each independently selected from hydrogen or C.sub.1-4alkyl; R.sup.4 represents hydrogen, halo, hydroxy, cyano, amino, NR.sup.11R.sup.12, C.sub.1-4alkyloxy-optionally substituted with one or where possible two or three substituents selected from hydroxy and halo or R.sup.4 represents C.sub.1-4alkyl optionally substituted with one or where possible two or three substituents selected from hydroxy and halo; R.sup.5 represents hydrogen, halo, cyano, amino, phenyl, hydroxy, C.sub.1-4alkyloxycarbonyl, hydroxycarbonyl, NR.sup.13R.sup.14 or C.sub.1-4alkyl substituted with one or more substituents selected from hydroxycarbonyl, phenyl, C.sub.1-4alkyloxy or NR.sup.15R.sup.16; R.sup.6 represents hydrogen; R.sup.11 and R.sup.12 each independently represent hydrogen, C.sub.1-4alkyl or C.sub.1-4alkylcarbonyl-; R.sup.13 and R.sup.14 each independently represent hydrogen, C.sub.1-4alkyl or C.sub.1-4alkylcarbonyl-; R.sup.15 and R.sup.16 each independently represent hydrogen, C.sub.1-4alkyl or C.sub.1-4alkylcarbonyl-; R.sup.17 and R.sup.18 each independently represent hydrogen, C.sub.1-4 alkyl or C.sub.1-4alkylcarbonyl-.